E-mail Updates- Home
- Search for Research Summaries, Reviews, and Reports
EHC Component
- EPC Project
Topic Title
Full Reports
- Research Review (Update) Nov. 19, 2007
- Appendixes (Update) Nov. 1, 2007
- Research Review Oct. 24, 2006
- Appendixes Oct. 24, 2006
Related Products for this Topic
- Consumer Summary Jun. 26, 2007
- La Guías Sumaria de los Consumidores Jul. 29, 2009
- Executive Summary Oct. 24, 2006
- Executive Summary (Update) Nov. 19, 2007
AHRQ's Healthcare 411 Audio/Video Features
Clinician Summary – Jun. 26, 2007
Management of Atherosclerotic Renal Artery Stenosis
Formats
- View PDF (PDF) 129 kB
- Help with Viewers, Players, and Plug-ins
Table of Contents
- Introduction
- Clinical Bottom Line
- Arteriogram
- Risks
- Still Unknown
- On the Horizon
- Resource for Patients
- Source
- For More Information
Introduction
This guide summarizes clinical evidence about the effectiveness and safety of angioplasty and medical therapy for treating atherosclerotic renal artery stenosis (ARAS). This guide does not address how to choose among diagnostic strategies for evaluating suspected ARAS, and it does not discuss renal artery stenosis due to fibromuscular dysplasia.
Clinical Issue
Atherosclerosis causes 90 percent of all renal artery stenosis, the narrowing of one or both renal arteries. It can adversely affect blood pressure and kidney function. Among people with diffuse atherosclerotic vascular disease, as many as half develop ARAS. Medical therapy with antihypertensive drugs can reduce blood pressure in most people with ARAS. While medical therapy can lower the risk of cardiovascular events, it does not always prevent deterioration of kidney function. Historically, surgical repair of the blocked artery was the definitive treatment for ARAS, but newer procedures have largely supplanted surgery. Currently, the most common method of improving renal artery blood flow is percutaneous balloon angioplasty with stent placement.
Clinical Bottom Line
Clinical Bottom Line
Overall, there is insufficient evidence to determine whether angioplasty with stenting is a better treatment for ARAS than aggressive medical therapy alone.
- There is no difference in the long-term kidney function of people who have angioplasty compared with people who have medical therapy alone.
Level of confidence:
- Both medical therapy and angioplasty lower blood pressure.Antihypertensive drugs generally lower blood pressure 20 - 50 mm Hg systolic and 8 - 42 mm Hg diastolic.The combination of angioplasty and antihypertensive drugs typically lowers blood pressure 6 - 32 mm Hg systolic and 0 - 17 mm Hg diastolic.
Level of confidence:
- Attainment of blood pressure control is more likely after angioplasty than with medical therapy alone.However, the benefit of angioplasty may be limited to people with bilateral disease.
Level of confidence:
- A small percentage of people who have had angioplasty plus stent (4 -18 percent) can discontinue blood pressure medications.
Level of confidence:
Confidence Scale
The confidence ratings in this guide are derived from a systematic review of the literature. The level of confidence is based on the number and quality of individual studies, duration of followup, and consistency across studies.
High
Consistent results from at least two high-quality studies with long-term follow up.
Findings are supported but are from fewer then two high-quality studies or from high-quality studies that lack long-term outcomes.Low
Results may be inconsistent or based on moderate to poor quality studies or studies of a population that may have little direct relevance to the question.
Arteriogram
Arteriogram Showing Renal Artery Stenosis
Image reproduced by permission from the Society for Vascular Surgery.
Risks
There are not enough data to compare the risks of adverse events for ARAS treatments, and there is insufficient evidence to determine whether rates of death or cardiovascular events differ between treatments. However, there is some information about the risks of each treatment.
Medication Risks
- The most common side effects of antihypertensive drugs are dizziness, sexual problems, headache, and cough.
Angioplasty Risks
- About 1 percent of people who have angioplasty die within the first 30 days after the procedure.
- 10 - 21 percent of people who have angioplasty with stent placement have restenosis within 40 months.
Still Unknown
- There are not enough data to know whether individual characteristics (such as baseline health status, diagnostic test results, or type of medications used for hypertension) have an effect on ARAS treatment outcomes.
- We do not know how different types of blood pressure medications compare in treating ARAS.
- There is insufficient evidence to determine whether angioplasty reduces the number of antihypertensive medications required after the procedure.
- There is no research about how angioplasty and medical therapy compare in treating people who have acutely decompensating hemodynamic and kidney function.
On the Horizon
Results from the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial
, currently underway, will be reported in 2010. This large, multi-center trial will examine whether patients with ARAS who undergo angioplasty with stent placement followed by aggressive medical treatment of hypertension have different outcomes than patients treated with aggressive medical treatment of hypertension alone.
Resource for Patients
Renal Artery Stenosis Treatments: A Guide for Consumers is a companion to this Clinician Summary. It can help people talk with their health care professional about ARAS. It provides information about:
- Types of ARAS treatments.
- Benefits and risks of ARAS treatments.
- Research findings about ARAS treatments.
- Seeking advice from a health care professional.
Source
The source material for this guide is a systematic review of 56 studies. The review,Comparative Effectiveness of Management Strategies for Renal Artery Stenosis (2006), was prepared by Tufts-New England Medical Center Evidence-based Practice Center. The Agency for Healthcare Research and Quality (AHRQ) funded the systematic review and this guide.
For More Information
For free print copies call:
The AHRQ Publications Clearinghouse, (800) 358-9295
Consumer's Guide, AHRQ Publication Number: 07-EHC004-2A
Clinician's Guide, AHRQ Publication Number: 07-EHC004-3
This guide was prepared by Sandra Robinson, M.S.P.H., Elizabeth Eckstrom, M.D., and David Hickam, M.D. of the Eisenberg Center at Oregon Health & Science University. They developed this guide using feedback from clinicians who reviewed preliminary drafts.
Return to Top of Page